Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

MiR-22 alleviates the proliferation and metastasis of melanoma by targeting FASN

Jun Qiu1, Yanhua Yi2, Yong Miao1, Zhiqi Hu1

1Department of Plastic and Aesthetic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China; 2Department of Aesthetic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, China.

For correspondence:-  Zhiqi Hu   Email: huzhiqidr163@i.smu.edu.cn   Tel:+862061641114

Accepted: 26 September 2022        Published: 28 October 2022

Citation: Qiu J, Yi Y, Miao Y, Hu Z. MiR-22 alleviates the proliferation and metastasis of melanoma by targeting FASN. Trop J Pharm Res 2022; 21(10):2043-2048 doi: 10.4314/tjpr.v21i10.1

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the role of microRNA-22 (miR-22) in the development of malignant melanoma, and the underlying mechanism.
Methods: Potential miRNAs binding fatty acid synthase (FASN) were predicted by bioinformatics analysis, out of which miR-22 was selected. Their binding relationship was confirmed using dual-luciferase reporter assay. MicroRNA-22 and FASN levels in 40 clinical samples of melanoma were determined, and the correlation of the expression between miR-22 and FASN was assessed by Pearson correlation test. To uncover the role of miR-22 in regulating cell phenotypes of malignant melanoma, M21 and A375 cells were transfected with miRNA-NC, miR-22 mimics or miR-22 mimics + FASN-OE (FASN-over expression), respectively. Proliferative and metastatic abilities in each group were determined using cell counting kit-8 (CCK-8), 5-Ethynyl-2’- deoxyuridine (EdU) and Transwell assay, respectively.
Results: MiR-22 was the target gene binding the oncogene, FASN. Downregulated miR-22 and upregulated FASN were observed in melanoma tissues, showing a negative correlation between them. An overexpression of miR-22 significantly inhibited proliferative, migratory and invasive capacities in M21 and A375 cells (p < 0.05). Notably, overexpression of FASN abolished the inhibitory effects of miR-22 on proliferative and metastatic abilities in melanoma.
Conclusion: The level of expression of miR-22 in the malignant melanoma samples is low. Overexpression of miR-22 inhibits the proliferative and metastatic abilities of melanoma by targeting FASN and negatively regulating its level. Thus, miR-22 may be a promising therapeutic target of melanoma.

Keywords: Malignant melanoma, MicroRNA-22, Fatty acid synthase, Proliferation, Metastasis

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates